| A dynamic, ultra-stable, random-access RNA retrieval database |
coordinator |
HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 |
€1,659,570 |
| CArdiovascularREsolution of INflammation to promote HEALTH |
participant |
HORIZON-HLTH-2022-STAYHLTH-02 |
€1,049,167 |
| NEUROendocrine SENSor for Sudden Unexpected Death in Epilepsy (SUDEP) pr |
participant |
HORIZON-EIC-2021-PATHFINDEROPEN-01 |
€936,745 |
| Promoting co-designed sustainable health interventions with young change |
coordinator |
HORIZON-HLTH-2023-DISEASE-03 |
€794,331 |
| Understanding the individual host response against Hepatitis D Virus to |
participant |
HORIZON-HLTH-2021-DISEASE-04 |
€761,250 |
| ADVANCING CLINICAL TRIALS AND EPIDEMIC PREPAREDNESS RESEARCH CAPACITY IN |
participant |
HORIZON-JU-GH-EDCTP3-2025-03-two-stage |
€749,155 |
| Restoring movement lost to stroke |
participant |
HORIZON-EIC-2024-PATHFINDEROPEN-01 |
€717,500 |
| EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEAS |
participant |
HORIZON-JU-GH-EDCTP3-2025-01-two-stage |
€706,980 |
| NATURE-INSPIRED PROPHYLACTIC LUBRICANTS AGAINST HIV-1 AND HSV-2 |
participant |
HORIZON-EIC-2023-PATHFINDEROPEN-01 |
€666,720 |
| Diagnostic and Antibiotic Stewardship for Urinary Tract Infections Using |
coordinator |
HORIZON-JU-GH-EDCTP3-2023-02-two-stage |
€599,625 |
| A holistic approach in patient management and epidemic surveillance thro |
participant |
HORIZON-HLTH-2021-DISEASE-04 |
€592,612 |
| MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar d |
participant |
HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 |
€590,625 |
| 2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using |
participant |
HORIZON-EIC-2022-PATHFINDEROPEN-01 |
€566,500 |
| REPRESSIT: A novel class of clinical immune checkpoint inhibitors |
participant |
HORIZON-EIC-2022-PATHFINDEROPEN-01 |
€514,510 |
| Safety and efficacy of Dolutegravir and EFV400 for pregnant and breastfe |
coordinator |
HORIZON-JU-GH-EDCTP3-2023-01 |
€500,000 |
| Heat Indicators for Global Health (HIGH Horizons): monitoring, Early War |
participant |
HORIZON-HLTH-2021-ENVHLTH-02 |
€499,976 |
| Advanced nanomaterials to target genomic and Z-DNA for bacterial biofilm |
participant |
HORIZON-EIC-2024-PATHFINDEROPEN-01 |
€450,625 |
| Instrument-free 3D molecular imaging with the VOLumetric UMI-Network EXp |
participant |
HORIZON-EIC-2024-PATHFINDEROPEN-01 |
€431,000 |
| EASTERN AFRICA CONSORTIUM FOR CLINICAL RESEARCH 4 |
participant |
HORIZON-JU-GH-EDCTP3-2025-03-two-stage |
€404,997 |
| BE READY NOW - EUROPEAN PARTNERSHIP FOR PANDEMIC PREPAREDNESS |
participant |
HORIZON-HLTH-2024-DISEASE-12 |
€396,694 |
| Endoscopic brush cytology and single cell clinal dynamics of early easop |
participant |
HORIZON-MISS-2023-CANCER-01 |
€323,875 |
| THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY |
participant |
HORIZON-HLTH-2022-DISEASE-06-two-stage |
€308,100 |
| Detection and characterization of cyclic di-GMP-binding proteins |
coordinator |
HORIZON-MSCA-2024-PF-01 |
€236,340 |
| Spatial profiling of gastric cancer with peritoneal carcinomatosis to ta |
coordinator |
HORIZON-MSCA-2024-PF-01 |
€236,340 |
| A revolutionary cell programming platform based on the targeted nano-del |
participant |
HORIZON-EIC-2022-PATHFINDEROPEN-01 |
€215,792 |
| Functional chemical reprogramming of cancer cells to induce antitumor im |
participant |
HORIZON-EIC-2023-PATHFINDEROPEN-01 |
€190,962 |
| Photonic chip based high-throughput, multi-modal and scalable optical na |
participant |
HORIZON-EIC-2021-TRANSITIONOPEN-01 |
€149,375 |
| NEW TECHNOLOGY FOR 1 MICRON RESOLUTION BIOMEDICAL IMAGING |
participant |
HORIZON-EIC-2024-PATHFINDEROPEN-01 |
€144,994 |
| FROM POPULATIONS TO CELLS AND BACK: Carcinogen Unmasking and Effect char |
participant |
HORIZON-MISS-2025-02 |
€135,000 |
| PROstate cancer Multimodal Explainable Transferable Holistic Expert for |
participant |
HORIZON-EIC-2025-PATHFINDERCHALLENGES-01 |
€114,274 |